Cargando…
Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
This manuscript on endpoints incorporates the broad experience of members of Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative as an open debate platform for academia, the pharmaceutical industry and regulatory experts surrounding the future design of clinical trials in...
Autores principales: | Sitbon, Olivier, Nikkho, Sylvia, Benza, Raymond, (CQ) Deng, Chunqin, Farber, Harrison W., Gomberg-Maitland, Mardi, Hassoun, Paul, Meier, Christian, Pepke-Zaba, Joanna, Prasad, Krishna, Seeger, Werner, Corris, Paul A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682238/ https://www.ncbi.nlm.nih.gov/pubmed/33282190 http://dx.doi.org/10.1177/2045894020962960 |
Ejemplares similares
-
Clinical trial design in phase 2 and 3 trials for pulmonary hypertension
por: Nikkho, Sylvia, et al.
Publicado: (2020) -
Updating clinical endpoint definitions
por: Hassoun, Paul M., et al.
Publicado: (2013) -
Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic
por: Ryan, John J., et al.
Publicado: (2020) -
The Innovative Drug Development Initiative (IDDI) of the Pulmonary Vascular Research Institute (PVRI): A series of four guidance documents for academics, drug regulators and industry partners
por: Corris, Paul A, et al.
Publicado: (2020) -
Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin
por: Al-Maatouq, M, et al.
Publicado: (2009)